Financing ·
BioLineRx Ltd. announced a registered direct offering and concurrent private placement on August 28, 2026, raising…
BLRXBioLineRx Ltd.
BioLineRx Ltd. announced a registered direct offering and concurrent private placement on August 28, 2026, raising $3.75 million in gross proceeds. The company sold 1,348,921 American Depositary Shares (ADSs) at $2.78 per ADS through exclusive placement agent Chardan. Concurrently, BioLineRx issued warrants to purchase up to 2,023,382 additional ADSs at the same price and exercise level, expiring in five years. The company also amended outstanding ordinary warrants held by the investor, reducing their exercise price to $2.78 per ADS and extending expiration to August 31, 2031. This transaction resulted in the reduction of the existing At-the-Market (ATM) Facility maximum aggregate offering amount to zero. Net proceeds are intended for research and development activities, working capital, and general corporate purposes. The closing is expected on or about August 31, 2026.